Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary ...

Results from GALILEO-1, a first in human clinical trial of FLT201 AAV-gene therapy in adult patients with Gaucher disease type 1 (Poster #318) Session: Poster Session III Date & Time: Thursday, ...

In accordance with ASX Listing Rule 4.7C, payments of A$126K made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, consulting fees, ...

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

A real-world cohort of patients with metastatic pancreatic adenocarcinoma (mPDAC) demonstrated that prophylaxis therapy to alleviate toxic effects was ...

Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

Daniel Andreas San Diego, 46, faces proceedings in the US over 'three bombings of two separate companies and the ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Nario, who completed an internship at Northeastern University’s Center for Theoretical Biophysics, is one of 50 RCC students who participate each year in internships through the school targeted at ...